News & Updates
Showing Pharmacy articles
Showing
Methotrexate may lower CV risk in psoriasis patients
Patients with psoriasis who are treated with methotrexate (MTX) show a reduced incidence of metabolic syndrome and better cardiometabolic profiles, according to a study presented at AAD 2026.
Methotrexate may lower CV risk in psoriasis patients
17 Apr 2026
Post-exposure PIP comparable to PrEP for low-risk HIV, but more affordable
Post-exposure prophylaxis-in-pocket (PIP) appears as effective as pre-exposure prophylaxis (PrEP) in improving quality of life (QoL) of individuals at low risk for HIV but may be a less costly option, according to a matched-control study presented at CROI 2026.
Post-exposure PIP comparable to PrEP for low-risk HIV, but more affordable
17 Apr 2026
Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS
Silymarin therapy combined with lifestyle interventions can reduce and normalize liver enzyme levels in patients with nonalcoholic fatty liver disease (NAFLD) and associated metabolic syndrome (MetS), a recent study has shown.
Silymarin plus lifestyle change improves liver health in NAFLD patients with MetS
16 Apr 2026
Gotistobart a chemo-free option for metastatic sqNSCLC
Gotistobart monotherapy elicits an improved and durable antitumour response with a meaningful survival benefit relative to docetaxel in patients with metastatic squamous nonsmall cell lung cancer (sqNSCLC) who experience disease progression on or after anti-PD-(L)1 treatment, as shown by the results of the stage 1 PRESERVE-003 phase III trial.